The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...
MedPage Today on MSN
Cemdisiran siRNA therapy demonstrates efficacy in myasthenia gravis
Investigational treatment improves outcomes without complete complement blockade ...
In recent years, the complement system has been implicated in the pathophysiology and progression of many disorders, notably modulating inflammation and causing endothelial and organ damage 1. Acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results